EORTC Shared Phase 2 EORTC-1612 EBIN Trial Results on First-Line Treatment Strategy in BRAF-Mutant Melanoma
EORTC – European Organisation for Research and Treatment of Cancer shared a post on LinkedIn:
“We have a new publication in The Lancet Oncology!
The results of the EORTC-1612 EBIN trial, comparing two treatment strategies for advanced melanoma, have been published.
This important study explored a critical clinical question: In patients with a BRAF V600E/K mutation, should targeted therapy or immunotherapy be given first?
Find out more.”
Title: Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced melanoma with BRAFV600E or BRAFV600K mutations (EBIN): an international, open-label, randomised, controlled, phase 2 study
Journal: The Lancet Oncology
Authors: Caroline Robert, Michal Kicinski, Caroline Dutriaux, Émilie Routier, Anne-Sophie Govaerts, Emanuel Bührer, Eve-Marie Neidhardt, Xavier Durando, Barouyr Baroudjian, Philippe Saiag, Caroline Gaudy-Marqueste, Paolo A Ascierto, Ana Arance, Michelangelo Russillo, Jean-Luc Perrot, Laurent Mortier, Francois Aubin, Stéphane Dalle, Florent Grange, Eva Muñoz-Couselo, Sorilla Mary-Prey, Mona Amini-Adle, Sandrine Mansard, Céleste Lebbe, Elisa Funck-Brentano, Sandrine Monestier, Alexander M M Eggermont, Felix Oppong, Leen Wijnen, Bastian Schilling, Mario MandalÁ, Paul Lorigan, Alexander C J van Akkooi
Also read OncoDaily’s special “Melanoma (Skin Cancer): Symptoms, Causes, Stages, Diagnosis and Treatment“.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023